Conditions

This post was originally published on this site Women in the European Union with BRCA-mutated advanced ovarian cancer can now receive Lynparza (olaparib) as a first-line maintenance treatment, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. The European Commission’s decision follows a positive recommendation from the Committee for Medicinal Products for Human Use…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Arvinas‘ lead protein degrader ARV-110 to treat patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after at least two prior therapies, the company announced. Therapies that target the androgen receptor, such…

This post was originally published on this site Aliqopa (copanlisib) has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed marginal zone lymphoma (MZL) who have received at least two prior therapies. The designation is intended to accelerate the development and review of…

This post was originally published on this site Europe’s umbrella organization for 800 rare disease associations has developed a sweeping initiative to help the continent’s 30 million rare disease patients and their caregivers learn about their conditions, find assistance and receive treatment. Eurordis-Rare Diseases Europe hopes to improve the current piecemeal treatment and support program with…

This post was originally published on this site Amgen’s investigational therapy AMG 212 (pasotuxizumab) is safe, and showing therapeutic activity against metastatic castration-resistant prostate cancer (mCRPC) in a Phase 1 clinical trial, data show. This is the first study suggesting that Amgen’s BiTE immunotherapy, designed to bring together patients’ immune T-cells and cancer cells, “can…

This post was originally published on this site Severe diarrhea is a side effect experienced by more than one-third of women with HER2-positive early-stage breast cancer receiving secondary treatment with Nerlynx (neratinib). But preventive treatment with loperamide (brand name Imodium A-D, among others) and other anti-diarrheal medications reduces the severity and duration of this complication,…

This post was originally published on this site Combining bemcentinib with Keytruda (pembrolizumab) has shown efficacy and led to longer survival than previous second-line treatments in patients with advanced non-small cell lung cancer (NSCLC), according to updated results of a Phase 2 trial. The research, “A phase II study of bemcentinib (BGB324), a first-in-class highly…

This post was originally published on this site The European Commision has converted the conditional approval of Servier‘s Pixuvri (pixantrone) into a standard marketing authorization, allowing the treatment’s use by people with aggressive non-Hodgkin’s B-cell lymphoma whose cancer has returned or has not responded to other chemotherapies, the company announced. Pixuvri is a chemotherapeutic agent that…

This post was originally published on this site Adding Darzalex (daratumumab) to the standard first-line treatment of Revlimid (lenalidomide) plus dexamethasone improves treatment and survival outcomes in multiple myeloma patients who are not eligible for an autologous stem cell transplant, a Phase 3 clinical trial shows. Findings from the MAIA trial (NCT02252172) were published in The New…

This post was originally published on this site To help find innovative ways to detect, treat, and prevent ovarian cancer, the Ovarian Cancer Research Alliance and the American Cancer Society plan to jointly invest $8 million in four multidisciplinary research projects, yet to be announced. The four-year initiative, which also seeks to prevent disease relapse…